© 2022 MJH Life Sciences and Cancer Network. All rights reserved.
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
November 16, 2015
This commentary addresses our perspectives from a regulatory standpoint, as well as some controversies related to the use of neoadjuvant therapy as a platform for drug development.